David Stamler
Net worth: 729 143 $ as of 2026-07-30
Net worth: 729 143 $ as of 2026-07-30
Dr. David A. Stamler, MD, is a Chief Executive Officer, MD & Director at Alterity Therapeutics Ltd. He is on the Board of Directors at Alterity Therapeutics Ltd. Dr. Stamler was previously employed as a Vice President-Clinical Development & Therapeutic by Teva Pharmaceutical Industries Ltd., a Chief Medical Officer by Auspex Pharmaceuticals, Inc., a Chief Medical Officer & Senior Vice President by XenoPort, Inc., a Chief Scientific Officer & Head-Drug Development by Prestwick Pharmaceuticals, Inc., a Senior Global Project Leader-CNS Diseases by Fujisawa Pharmaceutical Co., Ltd., a Vice President- Clinical Research Center by Astellas Research Institute of America LLC, a Vice President-Research & Development by Fujisawa Healthcare, Inc., and a Director-Clinical Research by Abbott Laboratories.
He received his undergraduate degree from The University of Chicago and a doctorate degree from Pritzker School of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-08-30 | 1,904,863 ( 0.88% ) | 729 143 $ | 2026-07-30 |
| Companies | Position | Start |
|---|---|---|
| ALTERITY THERAPEUTICS LIMITED | Chief Executive Officer | 2021-01-06 |
| Companies | Position | End |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 2016-12-31 |
| AUSPEX PHARMACEUTICALS INC | Chief Tech/Sci/R&D Officer | 2015-05-04 |
| XENOPORT, INC. | Chief Tech/Sci/R&D Officer | 2010-11-18 |
Prestwick Pharmaceuticals, Inc.
Prestwick Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for diseases related to the central nervous system | Chief Tech/Sci/R&D Officer | 2007-12-31 |
Fujisawa Pharmaceutical Co., Ltd.
Fujisawa Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceuticals and medical products | Corporate Officer/Principal | 2004-12-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 11 |
|---|---|
Abbott Laboratories
Abbott Laboratories Medical SpecialtiesHealth Technology Develops and manufactures medical devices, diagnostic systems, pharmaceuticals & nutritional products | Health Technology |
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
Fujisawa Pharmaceutical Co., Ltd.
Fujisawa Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceuticals and medical products | Health Technology |
Prestwick Pharmaceuticals, Inc.
Prestwick Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for diseases related to the central nervous system | Health Technology |
Alterity Therapeutics Ltd.
Alterity Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic drugs | Health Technology |
XenoPort, Inc.
XenoPort, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing of pharmaceutical products for the potential treatment of neurological disorders | Health Technology |
The University of Chicago
The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fujisawa Healthcare, Inc. | |
Astellas Research Institute of America LLC
Astellas Research Institute of America LLC Miscellaneous Commercial ServicesCommercial Services Operates as a pharmaceutical research & development company | Commercial Services |
Auspex Pharmaceuticals, Inc.
Auspex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Pritzker School of Medicine
Pritzker School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select your edition
All financial news and data tailored to specific country editions